NEW YORK, NY and SAN DIEGO, CA--(Marketwire - February 21, 2008) - Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (NASDAQ: CYPB) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for milnacipran for the treatment of fibromyalgia. With a standard 10-month review timeline, the FDA Prescription Drug User Fee Act (PDUFA) target action date is expected to occur by the end of October 2008.
